Hong Kong Electric Utilities Stock News

CGN Power (SEHK:1816) has wrapped up FY 2025 with fourth quarter revenue of about C¥16.0b and basic EPS of C¥0.023, while trailing twelve month revenue stood at roughly C¥75.7b with EPS of C¥0.193. Over recent periods, quarterly revenue has ranged from about C¥16.0b to C¥20.6b, with basic EPS moving between C¥0.023 and C¥0.06. This sets the backdrop for trailing net income of roughly C¥9.8b. With net profit margins ticking up slightly to 12.9% on a trailing basis, the latest results highlight...

Global markets have been navigating a challenging landscape marked by geopolitical tensions, fluctuating oil prices, and persistent inflation concerns. Amidst this backdrop, the concept of penny stocks remains relevant as these smaller or newer companies can offer unique growth opportunities at lower price points. When backed by strong financial health and solid fundamentals, penny stocks can present underappreciated chances for significant returns.

Akeso received regulatory clearance in China to start Phase II trials for two next generation antibody drug conjugates, AK146D1 and AK138D1, in oncology. The company also secured clearance for AK150, a globally first in class trispecific antibody, to begin clinical trials in patients with advanced solid tumors. These approvals move multiple assets in Akeso's pipeline into clinical and mid stage development. For investors tracking Akeso (SEHK:9926), these clearances come with the stock...

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) has received IND approval in China for SKB103, its first TAA PD-L1 bispecific antibody-drug conjugate. SKB103 becomes the company’s second bispecific ADC to reach the clinical stage, following SKB571. The candidate is built on Kelun-Biotech’s proprietary OptiDC™ platform and is designed to combine tumor antigen targeting with PD-L1 immune modulation. For investors tracking SEHK:6990, the IND clearance for SKB103 adds another clinical stage...

Amidst a backdrop of heightened uncertainty and inflation risks, Asian markets have been navigating through turbulent waters, influenced by global geopolitical tensions and fluctuating oil prices. Despite these challenges, the allure of penny stocks remains strong for investors seeking affordable entry points with potential for significant growth. Although considered a niche investment area today, penny stocks — typically smaller or newer companies — can offer promising opportunities when...

Earnings jump and dividend decisions put Kingboard Holdings (SEHK:148) in focus Kingboard Holdings (SEHK:148) reported full year 2025 results with higher sales and net income, alongside a larger final dividend and a special dividend. These developments have drawn attention to its recent shareholder payout decisions. See our latest analysis for Kingboard Holdings. Kingboard Holdings’ HK$35.36 share price has seen a 19.54% year to date share price return and a 23.03% 90 day share price return...

Even though Inspur Digital Enterprise Technology Limited ( HKG:596 ) has fallen by 10% over the past week , insiders...

Prosperity Real Estate Investment Trust (SEHK:808) has released its FY 2025 numbers with first half revenue of HK$205.8 million and basic EPS of HK$0.11 loss per unit, while the trailing twelve months point to revenue of HK$408.5 million and basic EPS of HK$0.16 loss. Over the past few reporting periods, the trust has seen revenue move from HK$214.9 million in 1H FY 2024 to HK$210.4 million in 2H FY 2024 and then to HK$205.8 million in 1H FY 2025, alongside basic EPS shifting between a...

As you might know, China Resources Beer (Holdings) Company Limited ( HKG:291 ) last week released its latest yearly...

Geely Automobile Holdings Limited's ( HKG:175 ) solid earnings announcement recently didn't do much to the stock price...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Insiders who bought Zhong Ying International Group Limited ( HKG:8516 ) stock in the last 12 months were richly...

As global markets grapple with heightened uncertainty, inflation risks, and geopolitical tensions, investors are increasingly looking toward stable income sources like dividend stocks. In the Asian market, where economic dynamics remain complex amid these challenges, selecting dividend stocks with solid fundamentals and reliable yields can offer a measure of stability in turbulent times.

Amidst a backdrop of global economic uncertainty and inflation risks, the Asian markets continue to navigate challenges with resilience. For investors willing to look beyond the well-known giants, penny stocks—often representing smaller or newer companies—can still offer intriguing opportunities. Though the term may seem outdated, these stocks can provide value when backed by strong financials and potential for growth.

As you might know, Minth Group Limited ( HKG:425 ) last week released its latest full-year, and things did not turn out...

Last week, you might have seen that China Overseas Grand Oceans Group Limited ( HKG:81 ) released its annual result to...

Zhaojin Mining Industry Company Limited ( HKG:1818 ) shareholders will have a reason to smile today, with the analysts...

Nexteer Automotive Group (SEHK:1316) opened FY 2025 with first half revenue of about US$2.2b and basic EPS of roughly US$0.03, against trailing twelve month figures showing basic EPS of about US$0.04 on revenue of roughly US$4.6b and earnings growth of 65.3% over the past year. Over the last three reported half year periods, revenue has moved from about US$2.1b in 1H FY 2024 to US$2.2b in 1H FY 2025, while basic EPS has shifted from roughly US$0.01 to about US$0.03 as net margins increased...

Cutia Therapeutics (SEHK:2487) opened FY 2025 with first half revenue of C¥66.3 million and a basic EPS loss of C¥0.75, while trailing twelve month revenue sat at C¥336.2 million against a basic EPS loss of C¥1.03. The company reported revenue of C¥95.6 million in the first half of 2024, C¥184.0 million in the second half of 2024, and C¥66.3 million in the first half of 2025, with basic EPS losses of C¥0.66, C¥0.75 and C¥0.75 over those same periods. This sequence highlights that investors...

AsiaInfo Technologies (SEHK:1675) has opened FY 2025 with first half revenue of C¥2.6b and a basic EPS loss of C¥0.22, setting a cautious tone for investors watching how the recent slowdown in profitability plays through the rest of the year. The company has seen first half revenue move from C¥3.0b in 2024, when EPS was a loss of C¥0.06, to C¥2.6b in 2025 alongside a trailing twelve month EPS of C¥0.13, leaving the latest results framed by thin margins and plenty of focus on how quickly...

Dongguang Chemical (SEHK:1702) has posted its FY 2025 results with first half revenue of CNY 1.2b and basic EPS of CNY 0.12, while trailing twelve month revenue came in at CNY 2.4b with basic EPS of CNY 0.23, set against a 65.5% earnings rise and a net profit margin of 5.9% for the period. Over recent periods the company has seen revenue move from CNY 1.34b in 2024 H1 to CNY 1.24b in 2024 H2 and CNY 1.18b in 2025 H1. Basic EPS shifted from CNY 0.15 in 2024 H1 to a small loss in 2024 H2 and...

Daphne International Holdings (SEHK:210) has reported its FY 2025 first half results with revenue of C¥198.3 million, basic EPS of C¥0.0327 and trailing 12 month earnings growth of 9.4% year over year. Over recent periods, the company has seen revenue move from C¥153.5 million in 2H 2024 to C¥198.3 million in 1H 2025, while trailing 12 month basic EPS has progressed from C¥0.0539 to C¥0.059. This sets the scene for investors to weigh these earnings against a 32.1% net profit margin that...

Huaneng Power International (SEHK:902) has wrapped up FY 2025 with fourth quarter revenue of C¥56.3b and basic EPS of C¥0.02 loss, against a backdrop of trailing twelve month EPS of C¥0.74 on revenue of C¥229.3b and a 99.8% year over year lift in earnings and net margin moving from 2.9% to 6.3%. Over recent periods, the company has seen quarterly revenue move from C¥61.2b in Q4 2024 to C¥60.9b in Q3 2025 and C¥56.3b in Q4 2025. Basic EPS shifted from a C¥0.83 loss in Q4 2024 to C¥0.30 in Q3...

China Medical System Holdings (SEHK:867) has secured Chinese regulatory approval for Desidustat Tablets, an oral treatment for renal anaemia in non dialysis adult chronic kidney disease patients, expanding its presence in the nephrology segment. See our latest analysis for China Medical System Holdings. The share price is at HK$13.27 after a 1 day share price return of 2.47%. However, the 30 day share price return shows a 14.05% decline, which contrasts with an 82.01% 1 year total shareholder...